Xinnate is a pharmaceutical development company in Lund, Sweden developing novel, pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbials and the complex interplay of inflammatory responses.
Xinnate runs an ambitious research and clinical program for TCP25 including a clinical study in phase 1b in patients with Epidermolysis bullosa (EB). Late-stage clinical development and commercialization will take place in partnership with one or more leading pharmaceutical companies.
Company Details
- Employees
- 9
- Founded
- 2019
- Address
- Scheeletorget 1, Lund,sweden
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- xinnate.com
- Keywords
- that ease the daily burdens of EB.
- HQ
- Lund
Xinnate Questions
Xinnate's website is xinnate.com
Xinnate's LinkedIn profile is https://se.linkedin.com/company/xinnate
Xinnate has
9 employees.
View email and phone details for 9
employees at Xinnate.
Xinnate's industry is
Pharmaceutical Manufacturing
Xinnate's top competitors are
Bioarctic,
Transient Pharma Ab,
Xintela Ab,
Gedea Biotech Ab,
Amplio Pharma,
Smile Venture Hub,
Hamlet Biopharma,
Redoxis Ab,
Bioinvent International Ab,
Truly Labs.
Xinnate's categories are Pharmaceutical Manufacturing
Xinnate's founding year is 2019
